Type 2 diabetes and fatty liver: new tests for disease tracking
Part of Hormones & metabolism clinical trials.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 80 years old.
- You have type 2 diabetes and fatty liver disease (seen on an ultrasound).
- You do not have cirrhosis (severe liver scarring) or a history of liver failure.
- You have not had heavy alcohol use (more than 2 drinks/day for men or 1 drink/day for women) in the past 10 years.
- You do not have other liver diseases like hepatitis B, hepatitis C, or autoimmune hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is checking people with type 2 diabetes for early signs of liver scarring (fibrosis) caused by MASLD, a common fatty liver condition. If you have diabetes and no known advanced liver damage, this screening could help find problems early.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study follows people with type 2 diabetes and a common liver condition called MASLD to see how their heart health changes over time. It aims to find better ways to prevent heart disease in people with both conditions.
Hear when a new Metabolic Dysfunction-Associated Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.